middle.news
Noxopharm Launches First Human Trial for SOF-SKN™ Targeting Lupus
8:37am on Thursday 29th of May, 2025 AEST
•
Biotechnology
Read Story
Noxopharm Launches First Human Trial for SOF-SKN™ Targeting Lupus
8:37am on Thursday 29th of May, 2025 AEST
Key Points
Human Research Ethics Committee approves HERACLES trial
First-in-human study of SOF-SKN™ drug candidate
Trial to test safety at four dosage levels
Recruitment and trial operations to begin in Australia
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Noxopharm (ASX:NOX)
OPEN ARTICLE